Role of tumour markers in monitoring epithelial ovarian cancer (Q33903011)

29 July 2017

8 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

7 August 2019

29 May 2020

20 July 2020

Role of tumour markers in monitoring epithelial ovarian cancer (English)

1 reference

29 July 2017

1 reference

7 August 2019

7 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

7 August 2019

1 reference

20 July 2020

1 reference

20 July 2020

Meyer T

1

1 reference

29 July 2017

Rustin GJ

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 2000

8 references

British Journal of Cancer

29 July 2017

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

7 August 2019

20 July 2020

9 references

29 July 2017

13 March 2019

14 March 2019

24 March 2019

3 April 2019

19 June 2019

7 August 2019

29 May 2020

20 July 2020

82

1 reference

29 July 2017

1535-1538

1 reference

29 July 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1174

29 July 2017

0 references

cites work

Screening for ovarian cancer: a pilot randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Elevation of multiple serum markers in patients with stage I ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Advanced ovarian cancer. Tumour markers.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Tumor markers in the management of patients with ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Reporting results of cancer treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Toxicity and response criteria of the Eastern Cooperative Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Reactivity of a monoclonal antibody with human ovarian carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Multimodal approach to screening for ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363391

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

29 October 2018

1 reference

12 December 2020

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

12 December 2020

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

1 reference

12 December 2020

Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses

1 reference

12 December 2020

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

1 reference

12 December 2020

The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients

1 reference

12 December 2020

The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer

1 reference

12 December 2020

A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer

1 reference

12 December 2020

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy

1 reference

12 December 2020

CA 125 for the monitoring of ovarian carcinoma during primary therapy

1 reference

12 December 2020

Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses

1 reference

12 December 2020

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

12 December 2020

Role of Ca 125 as tumor marker in ovarian carcinoma

1 reference

12 December 2020

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

12 December 2020

CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer

1 reference

12 December 2020

Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol

1 reference

12 December 2020

Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer

1 reference

12 December 2020

OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2000.1174

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference